Ionis Pharmaceuticals IONS
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 89th percentile, 5-year average -104.3x
Around its usual level · 48th percentile, 5-year average 14.9x
#5023 of 5331 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 0th percentile, 5-year average 8.8x
#3950 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 12.29 | – | 14.86 | 48% (cheaper than usual) | #5023 of 5331 (1 = cheapest) |
| PE | -8.67 | -8.00 | -104.26 | 89% (pricier than usual) | – |
| PS | 5.04 | 4.93 | 8.84 | 0% (cheaper than usual) | #3950 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on IONS.
Sign in to join the discussion.